We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Readministration of EGFR Tyrosine Kinase Inhibitor in Non-small Cell Lung Cancer Patients after Initial Failure, What Affects its Efficacy?
- Authors
Ze-Rui Zhao; Wei li; Hao Long
- Abstract
Few therapeutic options are available for non-small cell lung cancer (NSCLC) after failure to primary epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs). Since TKI rechallenge is one of the most common salvage approaches in clinical practice, we sought to identify the independent factors that associated with 2nd progression progression-free survival (PFS) and overall survival (OS). Seventy-two consecutive EGFR-mutated NSCLC patients with TKI retreatment after initial failure were retrospectively analyzed in this study. Univariate survival analysis and Cox proportional hazards regression model was used to determine if EGFR-TKIs readministration is tolerable as well as efficacious for a certain group of patients.
- Subjects
EPIDERMAL growth factor receptor genetics; EPIDERMAL growth factor receptors regulation; PROTEIN-tyrosine kinase inhibitors; PROTEIN-tyrosine kinase genetics; LUNG cancer patients; DRUG efficacy
- Publication
Scientific Reports, 2014, p1
- ISSN
2045-2322
- Publication type
Article
- DOI
10.1038/srep05996